Abstract
Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy in neurodegeneration, look at the results achieved and discuss the future perspectives.
Keywords: Microtubule, neurodegeneration, neuroprotection, therapy.
Current Pharmaceutical Design
Title:Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences
Volume: 23 Issue: 5
Author(s): Graziella Cappelletti, Daniele Cartelli, Michael S. Christodoulou and Daniele Passarella
Affiliation:
Keywords: Microtubule, neurodegeneration, neuroprotection, therapy.
Abstract: Around ten years ago, the first evidence that targeting microtubule system could be a potential strategy in slowing down neurodegeneration was reported. Several teams have been working to better shape this idea and the scientific community has now the opportunity of fishing into a large amount of data coming from in vitro and in in vivo studies. Notably, these results have driven clinical trials addressing tauopathies. Unfortunately, moving such a neuroprotective strategy from mice to men has revealed unexpected concerns and results that do not fit with the promising background. Here we aim to focus the rationale for the design of a microtubule-based therapy in neurodegeneration, look at the results achieved and discuss the future perspectives.
Export Options
About this article
Cite this article as:
Cappelletti Graziella, Cartelli Daniele, Christodoulou S. Michael and Passarella Daniele, Microtubule-Directed Therapeutic Strategy for Neurodegenerative Disorders: Starting From the Basis and Looking on the Emergences, Current Pharmaceutical Design 2017; 23 (5) . https://dx.doi.org/10.2174/1381612822666161214150544
DOI https://dx.doi.org/10.2174/1381612822666161214150544 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glutamate Receptors in Human Caudate Nucleus in Normal Aging and Alzheimer’s Disease
Current Alzheimer Research Mitochondrial Proteases as Emerging Pharmacological Targets
Current Pharmaceutical Design Heparin - a Key Drug in the Treatment of the Circulatory Degenerative Diseases: Controlling its Action with Polymers
Current Pharmaceutical Design Ketogenic Diets in the Treatment of Epilepsy
Current Pharmaceutical Design Editorial [Hot Topic:Role of Neural Stem Cells in Neurodegenerative Diseases:From the Molecule and Cell to the Clinic (Guest Editor: Oscar Gonzalez-Perez)]
Current Signal Transduction Therapy Anesthesia, Calcium Homeostasis and Alzheimers Disease
Current Alzheimer Research Exploring the Role of Aggregated Proteomes in the Pathogenesis of Alzheimer’s Disease
Current Protein & Peptide Science Biomarkers in Amyotrophic Lateral Sclerosis: Is There A Neurovascular Pathway?
Current Neurovascular Research Immunocal® and Preservation of Glutathione as a Novel Neuroprotective Strategy for Degenerative Disorders of the Nervous System
Recent Patents on CNS Drug Discovery (Discontinued) Cannabis sativa L. Constituents and Their Role in Neuroinflammation
Current Bioactive Compounds Hutchinson-Gilford Progeria Syndrome: An Overview of the Molecular Mechanism, Pathophysiology and Therapeutic Approach
Current Gene Therapy Identification of Human Acetylcholinesterase Inhibitors from the Constituents of EGb761 by Modeling Docking and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Editorial (Hot Topic: Therapeutic Targets in Neurodegenerative Diseases)
Current Enzyme Inhibition Dopamine D1 Receptors, Regulation of Gene Expression in the Brain, and Neurodegeneration
CNS & Neurological Disorders - Drug Targets Nanoparticle-Based Therapy in Genomics
Current Drug Metabolism Permeating the Blood Brain Barrier and Abrogating the Inflammation in Stroke: Implications for Stroke Therapy
Current Pharmaceutical Design Impacting Neuronal and Vascular Cellular Signal Transduction through the Metabotropic Glutamate Receptor System
Medicinal Chemistry Reviews - Online (Discontinued) Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Biocomputational Resources Useful For Drug Discovery Against Compartmentalized Targets
Current Pharmaceutical Design At the “Junction” of Spinal Muscular Atrophy Pathogenesis: The Role of Neuromuscular Junction Dysfunction in SMA Disease Progression
Current Molecular Medicine